Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A practical guide to PTSD treatment: Pharmacological and psychotherapeutic approaches.Atypical antipsychotics and anticonvulsants in the treatment of PTSD: Treatment options That include cognitive behavioral therapies.

A practical guide to PTSD treatment: Pharmacological and psychotherapeutic approaches.: Atypical... With limited medication options available for treating posttraumatic stress disorder (PTSD), there has been a growing interest in second-line agents that might address the core PTSD symptoms of reexperiencing, hyperarousal, and avoidance. This is especially true for patients who are refractory to the selective serotonin reuptake inhibitors (SSRIs) and the selective serotonin/norepinephrine reuptake inhibitor (SNRI) venlafaxine, which are recommended first-line agents in PTSD clinical practice guidelines (Foa, Keane, Friedman, & Cohen, 2009; U.S. Department of Veterans Affairs & Department of Defense, 2010). The atypical antipsychotics and the anticonvulsants are frequently used off-label treatments for PTSD despite limited data to support their use. Clinicians are often confronted with complex presentations of PTSD, including comorbid mood and substance use disorders that may include psychotic features. It is important to differentiate the core PTSD symptoms being targeted from the comorbid conditions for which the atypical antipsychotics and anticonvulsants have a more established role. This chapter explores the rationale for their use, along with concerns about their side effects and efficacy. Only randomized, placebo-controlled trials are considered. (PsycInfo Database Record (c) 2022 APA, all rights reserved) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A practical guide to PTSD treatment: Pharmacological and psychotherapeutic approaches.Atypical antipsychotics and anticonvulsants in the treatment of PTSD: Treatment options That include cognitive behavioral therapies.

Download PDF
10 pages

Loading next page...
 
/lp/american-psychological-association/a-practical-guide-to-ptsd-treatment-pharmacological-and-0ItS1DsaAM

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Psychological Association
Copyright
Copyright © 2015 American Psychological Association
ISBN
978-1-4338-1832-5
Pages
89 –99
DOI
10.1037/14522-007
Publisher site
See Chapter on Publisher Site

Abstract

With limited medication options available for treating posttraumatic stress disorder (PTSD), there has been a growing interest in second-line agents that might address the core PTSD symptoms of reexperiencing, hyperarousal, and avoidance. This is especially true for patients who are refractory to the selective serotonin reuptake inhibitors (SSRIs) and the selective serotonin/norepinephrine reuptake inhibitor (SNRI) venlafaxine, which are recommended first-line agents in PTSD clinical practice guidelines (Foa, Keane, Friedman, & Cohen, 2009; U.S. Department of Veterans Affairs & Department of Defense, 2010). The atypical antipsychotics and the anticonvulsants are frequently used off-label treatments for PTSD despite limited data to support their use. Clinicians are often confronted with complex presentations of PTSD, including comorbid mood and substance use disorders that may include psychotic features. It is important to differentiate the core PTSD symptoms being targeted from the comorbid conditions for which the atypical antipsychotics and anticonvulsants have a more established role. This chapter explores the rationale for their use, along with concerns about their side effects and efficacy. Only randomized, placebo-controlled trials are considered. (PsycInfo Database Record (c) 2022 APA, all rights reserved)

Published: Oct 13, 2014

Keywords: atypical antipsychotics; anticonvulsants; PTSD; treatment; cognitive behavioral therapy; adjunctive treatment

There are no references for this article.